Age-Related Macular Degeneration Market Report and Forecast 2024-2032

According to the report, the global age-related macular degeneration (AMD) market is projected to grow at a CAGR of 6.4% between 2024 and 2032 reaching a value of approximate USD 3.13 billion by 2032. Aided by the escalating global aging population and the increasing awareness of early AMD detection, the market is expected to grow significantly by 2032.

Age-related macular degeneration, commonly known as AMD, is a leading cause of vision loss in individuals aged 50 and above. It affects the macula, a tiny part of the retina responsible for sharp, central vision, gradually leading to blurred vision. While its early stages might have minimal symptoms, AMD can progress to a stage where it significantly hampers daily activities. Primarily categorised into dry (non-neovascular) and wet (neovascular) types, AMD presents a growing challenge to global health systems.

The stark rise in the aging population worldwide presents a pivotal driver for the age-related macular degeneration (AMD) market growth. As age is a significant risk factor for AMD, the expanding elderly demographic invariably translates to a heightened number of AMD cases, thereby pushing the demand for diagnostic and therapeutic solutions.

Moreover, global efforts to raise awareness about AMD and the importance of early detection have gained momentum. According to the age-related macular degeneration (AMD) market analysis, the regular eye examinations can identify the early signs of AMD, enabling timely interventions and potentially slowing the disease progression. Such awareness campaigns, often backed by governmental and non-governmental entities, have played a crucial role in driving the AMD market, as more individuals seek diagnostic consultations and treatment.

On the therapeutic front, while no cure exists for AMD, several treatments can slow its progression, especially for the wet type. The introduction of anti-VEGF agents has revolutionised the treatment landscape for neovascular AMD, offering significant vision improvements for many patients. As research intensifies, newer therapeutic agents with enhanced efficacy and fewer side effects are emerging, further propelling the market forward.

The positively influence on the age-related macular degeneration (AMD) market outlook is marked by relentless research and development. Efforts are underway to identify potential biomarkers for early AMD detection and to understand the underlying genetic and environmental factors, which could unlock preventive strategies in the future. Furthermore, as telemedicine and artificial intelligence gain traction, their integration into AMD diagnostics and monitoring promises to revolutionise patient care, offering remote, yet efficient, patient management.

Market Segmentation

The market can be divided based on product, drug, route of administration, and region.

Market Breakup by Product

• Wet AMD
• Dry AMD

Market Breakup by Drug

• Lucentis
• Eylea
• Avastin
• Others

Market Breakup by Route of Administration

• Intravenous
• Intravitreal

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Competitive Landscape

The report looks into the market shares, plant turnarounds, capacities, investments, and mergers and acquisitions, among other major developments, of the leading companies operating in the global age-related macular degeneration (AMD) market. Some of the major players explored in the report are as follows:

• Bayer AG
• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Regeneron Pharmaceuticals Inc. (NASDAQ: REGN)
• Others